In this trial, patients who had uterine serous carcinoma and who tested positive for human epidermal growth factor receptor 2 (HER2) / neu were randomized to either carboplatin plus paclitaxel (control arm) for six cycles or carboplatin plus paclitaxel plus IV trastuzumab (experimental arm).